Transmission and lesion progression of treponeme-associated hoof disease in captive elk (Cervus canadensis)
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0289764 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Zachary B Robinson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, Washington, United States …. Hauptthemen laut MEDLINE: Hoof and Claw, Digital Dermatitis, Deer, Treponemal Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Washington State University.
Abstract (Originalsprache)
Treponeme-associated hoof disease (TAHD) is a debilitating disease of free-ranging elk ( Cervus canadensis ) in the northwestern U.S. While treponemes are associated with lesions, the etiology and transmissibility between elk are unknown. Our objective was to determine whether the disease can be environmentally transmitted to captive elk. Four individually housed treatment elk and 2 control elk were challenged with soil mixed with inoculum prepared from free-ranging elk hooves from TAHD-positive elk or autoclaved hooves from normal elk, respectively. The inoculum for each group was applied to the interdigital space and added to pre-existing soil in each pen. Eight challenges were conducted at 1–4-week intervals and lesion development was assessed during a 138-day challenge period that was followed by a 170-day monitoring period to document lesion progression. All treatment elk, but no control elk, developed gross and histologic lesions consistent with TAHD. Treponema phylotypes similar to those in bovine digital dermatitis in cattle were detected using 16S rRNA gene amplicon sequencing from lesions in all treatment elk, but no control elk, during the challenge period. Lesions progressed from ulcerations in the interdigital space to extensive ulceration and underrunning of the hoof capsule by 35 and 173 days following the initial inoculation, respectively. Lameness in treatment elk was correlated with lesion development (R = 0.702, p≤0.001), and activity of infected elk was reduced during the challenge (p≤0.001) and monitoring periods (p = 0.004). Body condition was significantly lower in treatment than control elk 168 days following the initial inoculation (p = 0.05) and at each individual elk’s study endpoint (p = 0.006). Three of 4 treatment elk were euthanized when they reached humane endpoints, and one elk recovered. These results provide direct evidence that TAHD is a transmissible infectious disease in elk. As such, actions that reduce transmission risk can support disease management and prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, Washington, United States of America.
- School of Veterinary Medicine, Texas Tech University, Amarillo, Texas, United States of America.
- Washington Animal Disease Diagnostic Laboratory, Washington State University, Pullman, Washington, United States of America.
ORCID-Profile: Margaret A Wild
Förderung
- Washington State University
Zitieren
APA
Robinson, Z. B., Shah, D. H., Taylor, K. R., & Wild, M. A. (2023). Transmission and lesion progression of treponeme-associated hoof disease in captive elk (Cervus canadensis). PLOS ONE. https://doi.org/10.1371/journal.pone.0289764
Vancouver
Robinson ZB, Shah DH, Taylor KR, Wild MA. Transmission and lesion progression of treponeme-associated hoof disease in captive elk (Cervus canadensis). PLOS ONE. 2023. doi:10.1371/journal.pone.0289764
BibTeX
@article{Robinson2023,
author = {Robinson, Zachary B and Shah, Devendra H and Taylor, Kyle R and Wild, Margaret A},
title = {Transmission and lesion progression of treponeme-associated hoof disease in captive elk (Cervus canadensis)},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0289764}
}
EUVIMED